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Background: Hypoxia is a common characteristic of ali solid tumors.
The oxygen deficiency in tumor cells induces the expression of pro-
teins that promote the formation of metastases, angiogenesis, apop-
totic resistance, and metabolic adaptation. Hypoxic tumor cells have
an increased glycolytic activity. Glucose transporters and glycolytic
enzymes (hexokinase) have frequently been found to be overexpressed
in hypoxic tumor cells. These observations suggest that 18FDG can be
a suitable tracer for the detection of hypoxic regions, but in this respect,
however, the literature is contradictory. 18FAZA ([18F]-fluoro-azomyc-
inarabino-furanoside) is a widely used PET hypoxia-specific tracer. In
our work we have investigated the application of 18FAZA and 18FDG
for the detection of hypoxic areas of heterotopic xenograft tumors in
SCID mice.
Material and methods: Ten female CB17 SCID mice were used in these
experiments. A2780 ovarian carcinoma (3 x 106), and KB-3-1 cervix
karcinóma (3 x 106) cells were injected subcutaneously into the dorsal
region of the thigh. The development of tumors and the locations of
hypoxic areas were examined by MiniPET-1Iscanner. Radiopharmaceuti-
cals (4 ± 0.3 MBq 18FDG, or 7 ± 1 MBq 18FAZA) were injected via the
lateral tail vein. 40 min after 18FDG injection animai were anaesthetized
by 3% isoflurane with a dedicated small animai anaesthesia device.
20-min static single-frame PET scans were acquired using a small ani-
mai PET scan ner (MiniPET-II, Department of Nuclear Medicine, Debre-
cen) to visual ize the tumors. In case of 18FAZA we used static (120 min
after tracer injection) and dynamic scans. The PET data was evaluated
with BrainCAD software. The 18FDG and 11C-methionine uptake were
expressed in terms of standardised uptake values (SUVs) and tumor
to musele (T/M) ratios.
Results: 18FDG-MiniPET images showed heterogeneous radicphar-
maceutical accumulation in the investigated tumor xenografts. These
data indicated intensive glucose metabolism within the tumors. By
taking the SUV values we found differences between the highly positive
(SUVmean: 2.72 ± 0.23) and negative (SUVmean: 1.2 ± 0.36) tumor
areas. Significant differences were found in the case of 18FAZA. The
SUVmean values of the 18FAZA positive areas were 6-7 fold higher
than that of the negative areas. In the examined xenograft tumors there
were certain areas which were highly positive with both tracers (18FDG
and 18FAZA).
Coneiusion: Investigation of tumor hypoxia plays an important role in
the preclinical and clinical studies. Our in vivo MiniPET studies dern-
onstrated the specificity of 18FAZA in xenograft tumor models that
we used. Within the tumors the heterogenity of 18FDG accumulation
were similar to that observed with the use of 18FAZA, but the 6-7 fold
higher difference in the accumulation of 18FAZA between the hypoxic
and non-hypoxic areas demonstrated that for the detection of hypoxia
18FAZA is a more appropriate and specific radiotracer.
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Background: [18F] FDG produced by nucleophilic substitution method
followed by an acidic hydrolysis may contain two radiochemical
byproducts beside the active ingredient, name ly free [18F]-ions and
partially acetylated [18F]FDG as weil as inactive impurities FOG and
CIDG. To avoid the use of separate chromatographic methods for the
determination of radiochemical and chemical purity of the product
as recommended by Ph.Eur.6.2, in this work we report a new single
norm al phase HPLC method.
Material and methods: The HPLC system used for method develop-
ment consisted of an HPLC pump (Jasco). a syringe-Ioading sample
injector valve (Rheodyne), a radiometric detector (atomki, Hungary)
and a refractive index detector (Knauer). Standards of FDG and CIDG
were purchased from ABX GmbH.
Results: Using Inertsil NH2 column (4.6 mm x 250 mm; GL science,
Japan) at 1 mVmin flow rate with mobile phase acetonitrile/water 85/15 VI
N% we achieved the separation of FDG and CIDG with resolution of
1.74 ± 0.07, and the retention was 1.09 ± 0.04. The concentration of
FDG and CIDG standards was 100 J.1g/mL.The injected volume was
20 J.1L.The retention times of FDG and CIDG were 7.2 min and 8.2 min,
respectively. Under the same chromatographic conditions partially
acetylated [18F]FDG and [18F]FDG were eluted with retention tim es of
2.0 min and 7.0 min, respectively. In order to make free [18F]-ions eluted
we used gradient elution, with a flow rate 1 mVmin, and the eluent
composition was 85/15 VN% acetonitrile/water for 8 minutes. After that
the flow rate was 2 mi/min and the eluent composition was 5/95 VN%
acetonitrile/0.1 mM sodium acetate solution (pH6) for 7 minutes. Due
to gradient elution [18F] was eluted with a retention time of 12.4 min.
The resolution between partially acetylated [18F] FDG/[18F] FDG and
[18F]/[18F] FDG were 2.2 and 4.8, respectively. Tovalidate the analytical
method, we determined the linearity, precision and limit of quantifica-
tion. According to our results the RSD% of FDG peak height was 1.9%
(n = 3) and the [18F]FDG peak area was 0.07% (n = 8). The detector
response was linear for [18F]FDG in the range of 2-840 MBq/ml with
a coefficient of determination (r2) of 0.998. The LOO for [18F] and par-
tiallyacetylated [18F]FOG are 2.0 MBq/ml and 2.7 MBq/ml, respectively.
LOO for FOG and CIDG is 100 J.1g/mL.
Coneiusion: Our HPLC method gives an opportunity to decrease
the workload during the routine quality control of [18F]FDG at 5 ml of
maximum recommended dose of injection.
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FOR DETECTING MULTIDRUG RESISTANCE
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Background: Chemotherapy failure due to multidrug resistance (MDR)
is a common problem in cancer treatment, because of the overexpres-
sion of the drug efflux pump P-glycoprotein (Pgp). Detection of the
Pgp pump functions is an essential aspect in the treatment of cancer
patients. One of the promising methods in diagnostic imaging for in vivo
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detection of Pgp is the usage of radiolabeled substrates of Pgp. The
rhodamine family is a well-known substrate of Pgp that is widely used
in in vitro measurements. 18F-labeled rhodaminB (18FRB) gives a pos-
sibility for the in vivo experiment of the multidrug resistance of tumors.
In our study the application of the18F-labeled rhodaminB was tested on
3 different type multidrug resistance and sensitive cancer cell line pairs.
Material and methods: For in vitro study human cervix carcinoma
KB-3.1 Pgp negative and KB-V-1 Pgp positive, human ovarian carcinoma
A2780 Pgp negative and A2780AD Pgp positive and a mouse fibroblast
3T3 and 3T3MDR1 Pgp positive cell lines were used. The accumulation
of the 18FRB was measured by a calibrated gamma-counter. The Pgp
functions were tested with rhodamine 123 by flow-cytometry.
Results: Ali of the three Pgp positive cell lines were demonstrated that
the 18FRB is a potent Pgp substrate. The accumulation rates in the
Pgp negative cell lines were 52 (cervix carcinoma) 85 (ovarian carci-
noma) and 20 (libroblast) fold higher in contrast to the Pgp positive
cell lines. The treatment with cyclosporin A (CSA) - which is a Pgp
inhibitor - increased the 18FRB uptake ol Pgp positive cells close to
the level ol their negative pairs. The study of the accumulation kine-
tics showed that the 18FRB uptake reached a steady state level after
a few minutes (-10 minutes). In the presence ofverapamil the 18FRB
uptake was also higher in Pgp positive cells in contrast to the Pgp nega-
tive cells where a slightly lower uptake was observed. (not Pgp effect)
The Pgp lunctions were confirmed wi th avalidated fluorescent dye
(rhodamine 123) by Ilow-cytometry. The experiments in cell suspension
were completed with measurement of adherent cells in petri-dish by
MiniPET-1Iscanner. The results showed that 18FRB is a suitable tracer
for the demonstration of Pgp pump functions in both of suspension and
monolayer samples. Our results suggested that the 18FRB is proper
for detection of the changes of the mithocondrial membrane potential.
Conclusion: The 18F-labeled rodaminB sensitively indicates the func-
tion ol the Pgp pump in the multidrug resistant cancer cells. Further
biological studies are needed to demonstrate the applicability of the
18FRB in in vivo by PET imaging.
The study was support ed by grant Szodoray (Z.T Krasznai).
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APPLICATION OF MEDI-MEDIA-FILL KIT FOR
VERIFICATION AND VALIDATION OF ASEPTIC
COMPOUNDING PROCEDURE IN CLINICAL
PREPARATION SITES
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Our goal was to develop and provide a reagent and device kit which
makes possible to verify and validate directly the process on the spot ol
the production of parenterally administered therapeutic and diagnostic
radiopharmaceuticals in nuclear medicine.
The principles of aseptic pharmaceutical production and sterile product
compounding are discussed in the USP Chapter <797> in details.
The simulation test described in the kit is based on it. The aseptic
compounding process, which involves injecting, mixing, dispensing,
of sterile solutions, was simulated with sterile TSB microbiological
medium and sterile sealed vials in various volume sizes. The aseptic
process simulation test was combined with microbiological hygienic
monitoring of the environment and person ne ls using contact agar
plates. The result of the simulation test was visually assessed in micro-
biological tests alter incubation of test vials and plates for two weeks.
The test vials containing sterile TSB solution prepared in the simulation
test were examined for sterility. The hygienic conditions were evaluated
by examining the changes on contact agar plates used for sampling.
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The results of the tests are supplemented with the quantitative analy-
sis of bacterial endotoxin, the most aggressive and common pyrogenic
agent. The execution ol the aseptic simulation test was considered to
be conforrn to the requirements il each sample containing TSB medium,
which is aciear, transparent, light amber solution in sterile conditions,
retained its original properties, colony lormation on agar plates was not
seen, the quantity ol bacterial endotoxin in TBS solution did not exceed
the specilied limit value. To document the whole process in an easily
archivable lorm a data log sheet is attached to the kit where the data
and results can be recorded and summarized.
The Medi-Media-Fill kit is suitable and applicable lor ali sterile medici-
nal products produced in situ, in pharmacy laboratories including the
simulation of sterile aseptic compounding and dispending procedure ol
SPECT and PET radiopharmaceuticals intended for diagnostic use. The
aseptic conditions ol radiopharmaceutical production can be checked,
the operational steps can be validated, the person's experience involv-
ing in the compounding procedure can be demonstrated. The simulation
tests carried out by Medi-Media-Fill kit can also demonstrate and con-
lirm the good operation of the laboratory that in aseptic pharmaceutical
production meets the requirements of the authorities and inspectors,
and thus, it can ensure the sale diagnostical examinations.
Acknowledgements: Scientilic work was supported by European and
Hungarian project No KMPO-1.1.1-09/1-2009-0056.
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ANIMALS, USING TC-99M LABELED TARGETED
NANOPARTICLES
A. Polyák" 1.Hajdu", M. Bodnár", Z. Pöstényi', V Haász',
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Background: In our previous examinations, a new biocompatible, bio-
degradable sell-assembled nanoparticulate product was successlully
synthesized and radiolabelled with 99mTc, and studied as a potential
new SPECT or SPECT/CT imaging agent for diagnosis ol lolate receptor
overexpressing tumors. Besides this new polyelectrolyte was published
as a novel nanoscale drug carrier system and then presented as a new
lolate receptor targeting MRI contrast agent. In present study we exa-
mined possibility and conditions of the clinical veterinarian application of
these 99m Tc-Iabeled nanoparticles in early diagnosis of spontaneously
diseased animals using a human SPECT/CT
Material and methods: In course of labeling methods ol lolate targeted
nanoparticles, radiochemical purity was examined by thin layer chro-
matography, particle sizes were checked by dynamic light scattering.
Intracellular localization and toxicity ol the nanoparticles have been
reported in our previous papers.
In vivo experiments were performed on spontaneous diseased dog and
feline patients. Biodistribution values were determined by SPECT/CT
imaging method (Mediso Medical Imaging Systems), organ uptakes were
estimated by quantitative ROI analysis.
Results: The in vivo biodistribution examinations ol nanoparticles had
close correlation to earlier described products which have similar par-
ticle size distributions. Images and calculated injected dose perce nt-
age values validated that in vivo radiolabeling efficiency and particle
diameters were relative stable and constant after IV application.
The results conlirmed that the nanoparticles accumulated in tumour
cells overexpressing lolate receptors, contrast agent revealed higher
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